Whittier Trust’s BioCryst Pharmaceuticals BCRX Stock Holding History

Whittier Trust’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-146	Closed	-$1.04K	–	1360
2025 Q3	$1.04K	Buy	+146	New	+$1.22K	﹤0.01%	1323

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Whittier Trust's BCRX Position: Q4 2025 in Review

Whittier Trust sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 146 shares — an estimated $1.04K sold.

Whittier Trust first reported a position in BCRX in Q3 2025 and held it in 1 quarter. The position peaked at $1.04K in Q3 2025. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

Whittier Trust reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Whittier Trust sold 146 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $1.04K.
Whittier Trust first reported a position in BioCryst Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Whittier Trust's BioCryst Pharmaceuticals position peaked at $1.04K in Q3 2025.
272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Whittier Trust's 13F filing for Q4 2025, filed 26 Jan 2026.